ROLE OF ARTIFICIAL INTELLIGENCE IN PREDICTING OUTCOMES OF CLINICAL TRIALS IN ONCOLOGY

Authors

  • Dr Mayank Pancholi
  • Dr. Himanshu Patidar
  • Dr Kavin Rawal
  • Dr Vinod Dhakad
  • Dr Dharmesh Chouhan
  • Dr Jay Patel

DOI:

https://doi.org/10.53555/79vkpq57

Keywords:

................

Abstract

The field of oncology continues to face high attrition rates in clinical trials, with nearly 90% of investigational agents failing before market approval. This places enormous financial and ethical burdens on research institutions and patients alike. The advent of Artificial Intelligence (AI), particularly large language models (LLMs) and specialized neural networks, presents a promising strategy to enhance predictive accuracy for trial outcomes.

Objective: This study evaluates and compares the predictive performance of multiple AI architectures—including GPT-3.5, GPT-4, GPT-4mini, GPT-4o, LLaMA3, and the HINT model—in forecasting success or failure of oncology clinical trials using real-world datasets.

Methods: Oncology trial data were extracted from ClinicalTrials.gov. Structured trial inputs—phase, sponsor type, duration, endpoints, intervention class—were standardized across models. GPT-family and LLaMA3 models were accessed via API and prompted to classify trial outcomes. HINT, a structured AI model, was used with molecular and ICD-10 inputs. Performance was evaluated using Balanced Accuracy, Matthews Correlation Coefficient (MCC), Recall, and Specificity.

Results: GPT-4o demonstrated the highest balanced accuracy (0.573) and robust recall (0.931), while HINT achieved the best specificity (0.541) and stable MCC (0.111). All models underperformed in predicting outcomes for complex oncology subtypes and longerduration trials.

Conclusion: AI models hold significant promise in improving predictive capabilities for oncology trial outcomes. GPT-4o and HINT exhibit complementary strengths, and ensemble approaches may optimize trial design, patient selection, and resource allocation.

Author Biographies

  • Dr Mayank Pancholi

    Designation professor and HOD, Department Surgical Oncology, College/University Name Sri Aurobindo Institute of Medical Sciences, Indore, City- Indore,

  • Dr. Himanshu Patidar

    Designation Associate Professor, Department Surgical Oncology, College/University Name Sri Aurobindo Institute of Medical Sciences, Indore, City Indore,

  • Dr Kavin Rawal

    Designation Senior Resident, Department Surgical Oncology, College/University Name Sri Aurobindo Institute of Medical Sciences, Indore, City Indore,

  • Dr Vinod Dhakad

    Designation Professor, Department Surgical Oncology, College/University Name Sri Aurobindo Institute of Medical Sciences, Indore, City Indore,

  • Dr Dharmesh Chouhan

    5Designation Senior Resident, Department Surgical Oncology, College/University Name Sri Aurobindo Institute of Medical Sciences, Indore, City Indore,

  • Dr Jay Patel

    Designation Senior Resident, Department Surgical Oncology, College/University Name Sri Aurobindo Institute of Medical Sciences, Indore, City Indore,

References

1. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–385.

2. Mallath MK, Taylor DG, Badwe RA, et al. The growing burden of cancer in India: epidemiology and social context. Lancet Oncol. 2014;15(6):e205–12.

3. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56.

4. Goel I, Bhaskar Y, Kumar N, Singh S, Amanullah M, Dhar R, Karmakar S. Role of AI in empowering and redefining the oncology care landscape: perspective from a developing nation. Front Digit Health. 2025 Mar 4;7:1550407.

5. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters in oncology. Biostatistics. 2019;20(2):273–286.

6. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry:

new estimates of R&D costs. J Health Econ. 2016;47:20–33.

7. Siu LL, et al. Challenges and opportunities in adapting clinical trial design for immunotherapies. Clin Cancer Res. 2017;23(17):4990–5000.

8. Fu J, et al. Predicting clinical trial outcomes using deep learning. Nat Mach Intell. 2022;4:834–845.

Downloads

Published

2025-11-29

How to Cite

Dr Mayank Pancholi, Dr. Himanshu Patidar, Dr Kavin Rawal, Dr Vinod Dhakad, Dr Dharmesh Chouhan, & Dr Jay Patel. (2025). ROLE OF ARTIFICIAL INTELLIGENCE IN PREDICTING OUTCOMES OF CLINICAL TRIALS IN ONCOLOGY. Journal of Population Therapeutics and Clinical Pharmacology, 32(10), 1656-1661. https://doi.org/10.53555/79vkpq57
More Citation Formats

Issue

Section

Articles

How to Cite

Dr Mayank Pancholi, Dr. Himanshu Patidar, Dr Kavin Rawal, Dr Vinod Dhakad, Dr Dharmesh Chouhan, & Dr Jay Patel. (2025). ROLE OF ARTIFICIAL INTELLIGENCE IN PREDICTING OUTCOMES OF CLINICAL TRIALS IN ONCOLOGY. Journal of Population Therapeutics and Clinical Pharmacology, 32(10), 1656-1661. https://doi.org/10.53555/79vkpq57